This article, "Despite Rituximab's Promise in Neurology, Roche Focuses on Ocrelizumab," came to my attention. The Website--the Center for Biosimilars--is unfamiliar to me but its contributors are people with mainstream credentials. Though the article covers ground that has been discussed here before, it also mentions the upcoming ECTRIMS conference (Paris, October 25-28) at which the pharmaceutical giant Roche--owners of Genentech, which makes these two drugs--will be presenting a mountain of evidence in favor of Ocrevus:
Only registered and activated users can see links., Click Here To Register...
Only registered and activated users can see links., Click Here To Register...

Please Note that my posts may have been arbitrarily altered by a Moderator and may not reflect my original content.
Comment